Metronidazole 250mg Tablet Franchise in Ahmedabad

Antibacterial & Antiprotozoal Therapy Supplier in Mumbai

Metofoli 250 Tablet Distributor in Delhi

Gastrointestinal & Gynecological Infection Tablet Franchise Opportunity in Bangalore

Anaerobic Infection Tablet Stockist in Hyderabad
Metronidazole 250mg Export & Manufacturing in Chandigarh

Home/Products /metronidazole-250mg-tablet

Metofoli 250 Tablet

Composition : Metronidazole (250mg) Tablet

Dosage Form : Tablet

Packaging Type : Blister

Packaging : 10*10

Price : ₹1/-

Metofoli 250 Tablet contains Metronidazole 250mg, a potent antibacterial and antiprotozoal agent indicated for the treatment of infections caused by anaerobic bacteria and protozoa, including gastrointestinal, gynecological, and parasitic infections. It helps in controlling microbial proliferation and alleviating infection-related symptoms.

Metronidazole works by inhibiting nucleic acid synthesis in susceptible microorganisms, causing cell death and effective eradication of the infection. Its broad-spectrum action ensures reliable management of bacterial and protozoal infections.

For distributors and healthcare suppliers, Metofoli 250 Tablet is a high-demand anti-infective product, widely prescribed in hospitals, clinics, and community healthcare setups. Its regular use for gastrointestinal and gynecological infections guarantees stable market turnover.

Adding Metofoli 250 Tablet to your antibacterial and antiprotozoal therapy segment creates strong opportunities in pharmacies, hospitals, specialty clinics, export markets, and third-party manufacturing. Its proven clinical efficacy, broad applicability, and strong prescriber trust make it a valuable addition to pharmaceutical distribution portfolios.

Read More

About the Product

Metofoli 250 Tablet contains Metronidazole 250mg, a potent antibacterial and antiprotozoal agent indicated for the treatment of infections caused by anaerobic bacteria and protozoa, including gastrointestinal, gynecological, and parasitic infections. It helps in controlling microbial proliferation and alleviating infection-related symptoms.

Metronidazole works by inhibiting nucleic acid synthesis in susceptible microorganisms, causing cell death and effective eradication of the infection. Its broad-spectrum action ensures reliable management of bacterial and protozoal infections.

For distributors and healthcare suppliers, Metofoli 250 Tablet is a high-demand anti-infective product, widely prescribed in hospitals, clinics, and community healthcare setups. Its regular use for gastrointestinal and gynecological infections guarantees stable market turnover.

Adding Metofoli 250 Tablet to your antibacterial and antiprotozoal therapy segment creates strong opportunities in pharmacies, hospitals, specialty clinics, export markets, and third-party manufacturing. Its proven clinical efficacy, broad applicability, and strong prescriber trust make it a valuable addition to pharmaceutical distribution portfolios.

Common side effects may include nausea, vomiting, metallic taste, diarrhea, or mild abdominal discomfort. Rare but serious effects include allergic reactions, seizures, peripheral neuropathy, or liver dysfunction. Patients should seek immediate medical attention if severe or persistent symptoms occur.

Metofoli 250 Tablet is indicated for the treatment of infections caused by anaerobic bacteria, bacterial vaginosis, amoebiasis, giardiasis, trichomoniasis, and other protozoal infections as directed by a healthcare professional.

Before taking Metofoli 250 Tablet, inform your doctor if you have liver disease, neurological disorders, or known hypersensitivity to nitroimidazoles. The full course of the tablet should be completed even if symptoms improve, and alcohol should be avoided during therapy.

Store Metofoli 250 Tablet in a cool, dry place away from direct sunlight and moisture. Keep out of reach of children and ensure the blister pack is intact. Do not use the tablet beyond its expiry date.

Get in Touch

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Strategic Advisory

Ms. Shiwani Dhiman

VP-Strategic Outreach & Engagement

Ms. Shiwani specializes in market outreach and strategic partnership orchestration for entrepreneurs building scalable PCD Pharma Franchise models.

View Professional Profile

Start Your Journey

Partner With Cafoli

Ready to Dominate your territory with a Monopoly-Based PCD Franchise? Join our rapidly growing network of successful franchise partners and turn your ambitions into reality. Limited Territories Available — Don’t Miss Out!

Quick Navigation